On January 5, 2026, GE HealthCare informed shareholders that it had received an unsolicited mini-tender proposal from Potemkin Limited seeking to acquire up to 100,000 GE HealthCare shares in a cash transaction at a per-share price nearly 35% below the company’s recent closing level. GE HealthCare’s board and management cautioned investors that this offer undervalues the business and carries significant execution and liquidity risks, recommending that shareholders refrain from tendering their stock. The firm highlighted that accepting the offer would permanently forfeit participation in potential future gains tied to its $19.7 billion global healthcare solutions franchise and its ongoing investments in AI-enabled diagnostics and patient care systems.

GE HealthCare has partnered with NXP Semiconductors to develop and demonstrate two proof-of-concept edge AI applications tailored for anesthesiology and neonatal intensive care. Unveiled at CES 2026, the first concept enables hands-free, voice-command interaction with anesthesia delivery equipment, designed to reduce cognitive load and alarm fatigue for clinicians in high-stress operating rooms. The second prototype delivers real-time, on-device monitoring in the NICU, using secure local image analysis to detect infant distress signals—such as crying, abnormal positioning, or foreign objects in the crib—and issue actionable alerts. Both innovations leverage NXP’s integrated neural processing units and GE HealthCare’s Responsible AI principles, underscoring the company’s commitment to secure, low-latency intelligence at the point of care.